光线性角化病患者皮肤癌风险:Medicare队列研究
结果显示,AK患者1年、3年、5年皮肤癌绝对风险分别为6.3%、18.4%、28.5%,且相对于SK患者,任何皮肤癌、角质形成细胞癌、SCC、BCC和黑色素瘤的风险均显著升高。
要点
- AK患者5年内皮肤癌绝对风险达28.5%。
- AK患者任何皮肤癌风险是SK患者的2.17倍。
- AK患者SCC风险升高最显著(aHR 2.63)。
核心结论
- AK患者皮肤癌绝对风险和相对风险均显著升高,AK可能是紫外线暴露和皮肤癌风险的临床标志。
研究设计与样本
- 排除有皮肤癌病史者,要求入组至首次AK或SK诊断至少间隔1年。
主要发现
- 首次AK后皮肤癌绝对风险:1年6.3%(95% CI 6.3%-6.4%),3年18.4%(95% CI 18.3%-18.5%),5年28.5%(95% CI 28.4%-28.7%)。
- 与SK患者相比,AK患者任何皮肤癌aHR 2.17(95% CI 2.15-2.19),角质形成细胞癌aHR 2.20(95% CI 2.18-2.22)。
- AK患者SCC的aHR 2.63(95% CI 2.59-2.66),BCC的aHR 1.85(95% CI 1.82-1.87),黑色素瘤的aHR 1.67(95% CI 1.60-1.73)。
临床怎么用
- AK患者应被视为皮肤癌高危人群,需关注SCC、BCC及黑色素瘤的监测。
- 目前缺乏AK患者皮肤癌随访监测指南,需制定循证建议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Actinic keratoses (AK) are common premalignant skin lesions with a small risk of progressing to cutaneous squamous cell carcinoma (SCC). There is some evidence that patients with AKs also have increased risks of other skin cancers beyond SCC. However, the absolute risks of skin cancer in patients with AKs are unknown. OBJECTIVE: To calculate the absolute and relative risks of future skin cancer in Medicare beneficiaries with AKs. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was performed using a deidentified, random sample of 4 999 999 fee-for-service Medicare beneficiaries from 2009 through 2018. Patients with treated AKs were included, and patients with seborrheic keratoses (SKs) were included as a comparator group. All patients were required to have at least 1 year between data set entry and first AK or SK. Patients with a history of skin cancer were excluded. Data were analyzed from September 2022 to March 2023. MAIN OUTCOMES AND MEASURES: Outcomes were first surgically treated skin cancer, including keratinocyte carcinoma (including SCC and basal cell carcinoma [BCC]) and melanoma. The absolute risks of skin cancer in patients with AKs were evaluated. Skin cancer risks in patients with AKs were compared with patients with SKs using adjusted competing risks regression. RESULTS: A total of 555 945 patients with AKs (mean [SD] age, 74.0 [7.4] years; 55.4% female) and 481 024 patients with SKs (mean [SD] age, 73.3 [7.3] years; 72.4% female) were included. The absolute risk of skin cancer after a first AK was 6.3% (95% CI, 6.3%-6.4%) at 1 year, 18.4% (95% CI, 18.3%-18.5%) at 3 years, and 28.5% (95% CI, 28.4%-28.7%) at 5 years. Patients with AKs had increased risk of skin cancer compared with patients with SKs (any skin cancer: adjusted hazard ratio [aHR], 2.17; 95% CI, 2.15-2.19; keratinocyte carcinoma: aHR, 2.20; 95% CI, 2.18-2.22; SCC: aHR, 2.63; 95% CI, 2.59-2.66; BCC: aHR, 1.85; 95% CI, 1.82-1.87; and melanoma: aHR, 1.67; 95% CI, 1.60-1.73). CONCLUSIONS AND RELEVANCE: In this cohort study, older patients with AKs had substantial absolute risks, as well as elevated relative risks, of skin cancer. AKs may be clinical markers of UV exposure and increased skin cancer risk, including SCC, BCC, and melanoma. However, guidelines are lacking for follow-up skin cancer surveillance in patients with AKs. Efforts to develop evidence-based recommendations for skin cancer surveillance in patients with AKs are paramount.
引用
- Mohr C, Li Y, Navsaria LJ, et al. Skin Cancers in Medicare Beneficiaries With Actinic Keratoses. JAMA Dermatol. 2023. PMID: 37938822. doi:10.1001/jamadermatol.2023.4266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。